Karger - Fast Facts Oncology Karger Publishers

This is the third episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management.
In this episode, Dr. DiNardo discusses the missing pieces of MDS management, starting with the latest approvals in MDS treatment and how eligibility for clinical trials is assessed. She also touches on which impacts of transplantation or transformation to acute myeloid leukemia (AML) can be managed. She also touches on the cutting-edge genetic insights that might deliver on the promise of personalized medicine to MDS patients with the most challenging diagnoses.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the second episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management.
In this episode, Dr. Griffiths discusses what makes Real World Evidence and how it is obtained or archived, the risk stratification of MDS and what that means for gathering evidence, and bridging the gap between the best outcomes of clinical trials and the down-to-Earth results seen in daily clinical practice.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the first episode in our series on myelodysplastic syndromes which aims to update clinicians on the latest developments in their diagnosis and management.
In this episode, Dr. DeFilipp outlines the current and upcoming treatments for myelodysplastic syndromes. He discusses doublet and triplet combinations that are moving the needle on disease management, including emerging therapies and combinations of hypomethylating agents. He also considers which underlying mutations pose the greatest challenges and/or provide the greatest opportunities for future research in the field.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the third episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management.
In this episode, Melinda Bachini discusses the use of biomarker testing in cholangiocarcinoma. From the perspective of a patient advocate, she explains how to relay complex information about biomarker testing to patients, and outlines what patients really want to know. She provides advice on how to empower patients to navigate their diagnosis and be the best patient advocates they can possibly be.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc.  The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse  the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.

This is the second episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management.
In this episode, Dr. Marina Baretti discusses the safety of fibroblast growth factor receptor (FGFR) inhibitors, drawing from her clinical experience. She details current safety data, and explains what you need to know about the management of their side effects and adverse events.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc.  The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse  the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.
 

This is the first episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management.
In this episode, Dr. Sameek Roychowdhury discusses fibroblast growth factor receptor (FGFR) inhibitors in the management of cholangiocarcinoma—how long they’ve been in use, and what we know about their efficacy and toxicity. He uses his clinical experience to share what clinicians really need to know about this treatment, and what to do when disease progresses while on this treatment.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.